Your browser doesn't support javascript.
loading
Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases.
Liefferinckx, Claire; Verstockt, Bram; Gils, Ann; Tops, Sophie; Van Moerkercke, Wouter; Vermeire, Severine; Franchimont, Denis.
Afiliación
  • Liefferinckx C; Department of Gastroenterology, Hôpital Erasme, ULB, Brussels, Belgium.
  • Verstockt B; Laboratoire de gastroenterology experimentale, ULB, Brussels, Belgium.
  • Gils A; University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium.
  • Tops S; KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium.
  • Van Moerkercke W; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium.
  • Vermeire S; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium.
  • Franchimont D; University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium.
United European Gastroenterol J ; 7(6): 750-758, 2019 07.
Article en En | MEDLINE | ID: mdl-31316779
ABSTRACT

Background:

Very little is known about the impact of the wash-out period on the pharmacokinetics of a second-line biologic.

Objective:

The objective of this article is to explore the impact of two different wash-out periods on the pharmacokinetics of vedolizumab and infliximab.

Methods:

Patients switching from infliximab to vedolizumab were retrospectively identified. The population was divided into two groups according to wash-out period <6 weeks or >6 weeks. Vedolizumab and infliximab trough levels (TLs) were determined and correlated with clinical and biological outcomes.

Results:

A total of 71 inflammatory bowel disease patients were included. At week 6, in patients previously treated with infliximab, median vedolizumab TLs were 21.9 µg/ml and 24.9 µg/ml for the <6 weeks and >6 weeks wash-out period, respectively (p = 0.31), whereas median residual infliximab TLs were 0.5 µg/ml and 0 µg/ml (p = 0.034). The rate of treatment discontinuation was similar (p = 0.64), and the infectious events were six and two for the <6 weeks and >6 weeks wash-out period, respectively (p = 0.12) by week 30.

Conclusions:

This study suggests clinicians may not need to be concerned about the impact of wash-out period on the pharmacokinetics of the second-line biologic when switching infliximab to vedolizumab. More data are required on the impact of wash-out period on safety.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: United European Gastroenterol J Año: 2019 Tipo del documento: Article País de afiliación: Bélgica

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: United European Gastroenterol J Año: 2019 Tipo del documento: Article País de afiliación: Bélgica
...